Zealand Pharma AS (STU:22Z) FFO


STU:22Z Zealand Pharma AS STU:22Z
56 GF Score
Price €37.40
GF Value €1,709.98
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Zealand Pharma AS FFO?

FFO (Funds from operations) only applies to REITs.

STU:22Z
56GF Score
Zealand Pharma AS STU:22Z
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zealand Pharma AS (STU:22Z) Overvalued in 2026?

Based on GuruFocus' analysis, Zealand Pharma AS stock appears to be undervalued. The current stock price of €37.40 is trading 97.8% below its estimated GF Value™ of €1,709.98. GuruFocus considers Zealand Pharma AS to be Possible Value Trap.

Key valuation signals for STU:22Z:

  • FFO:
  • GF Value™: €1,709.98 vs. price of €37.40 (97.8% below fair value)
  • GF Score™: 56/100 with 3 warning signs

No single metric tells the full story. See the STU:22Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
56GF Score

Get the complete analysis for STU:22Z

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€37.40
Price
€1,709.98
GF Value